Archie Cullen Named President of BioReliance - - BioPharm International


Archie Cullen Named President of BioReliance

SAFC, the custom manufacturing and services business unit of Sigma-Aldrich, has appointed Archie Cullen as the new president of BioReliance, SAFC’s biologics and early development services business. Cullen replaces Charles Harwood, who is retiring following the acquisition of BioReliance by Sigma-Aldrich in January 2012 and the subsequent integration of BioReliance into SAFC over the past year. In his previous position as vice president of SAFC, Cullen was involved in the acquisition of BioReliance.

"Being able to go to market with our product offerings complemented by an integrated testing platform is expected to create a great opportunity for SAFC to enable new product and service solutions to our customers," stated Cullen in a press release. "Right now, each business is benefiting from its ability to introduce and reintroduce each other to the respective customer bases. My role will be to support a go-to-market approach with a coordinated offering from raw materials to testing. That's what our larger customers have been requesting."

Cullen's career includes a range of global experience in the biopharma sector, including time with Life Technologies and JRH Biosciences. Following the acquisition in 2005 by Sigma-Aldrich, Cullen became vice president of commercial and technical operations for SAFC's biosciences business unit where he was responsible for the organization's global sales, marketing, research and development functions. In 2009, he was promoted to vice president of sales for SAFC where he headed up strategic accounts globally. Cullen holds a Bachelor of Science degree from the University of Glasgow and a Master of Business of Administration degree from Open University.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here